60 Degrees Pharmaceuticals (SXTP) Common Equity (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Common Equity of $4.8 million for Q1 2026, up 19.86% year-over-year from $4.0 million in Q1 2025, and up 39.44% quarter-over-quarter from $3.5 million in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Common Equity (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Common Equity for 5 consecutive years, with $4.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 19.86% year-over-year to $4.8 million; the TTM figure through Mar 2026 stood at $4.8 million (up 19.86% YoY), while the FY2025 annual figure was $3.5 million, down 12.44% from the prior year.
- Common Equity rose to $4.8 million in Q1 2026 per SXTP's latest filing, from $3.5 million in the prior quarter.
- Across five years, Common Equity topped out at $7.1 million in Q1 2024 and bottomed at -$24.7 million in Q2 2023.
- Historically, Common Equity has averaged -$4.0 million across 5 years, with a median of $3.7 million in 2024.
- Annual changes were most pronounced in 2024 — Common Equity jumped 133.34% — and 2025, when it plunged 43.46%.
- 60 Degrees Pharmaceuticals' Common Equity stood at -$24.1 million in 2022, then surged by 119.87% to $4.8 million in 2023, then fell by 17.57% to $4.0 million in 2024, then declined by 12.44% to $3.5 million in 2025, then jumped by 39.44% to $4.8 million in 2026.
- Business Quant data shows SXTP's Common Equity at $4.8 million in Q1 2026, $3.5 million in Q4 2025, and $4.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 9.79 Bn |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | 2.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.83 Mn |
| Dec 31, 2025 | 3.46 Mn |
| Sep 30, 2025 | 4.43 Mn |
| Jun 30, 2025 | 2.35 Mn |
| Mar 31, 2025 | 4.03 Mn |
| Dec 31, 2024 | 3.96 Mn |
| Sep 30, 2024 | 5.96 Mn |
| Jun 30, 2024 | 2.96 Mn |
| Mar 31, 2024 | 7.13 Mn |
| Dec 31, 2023 | 4.80 Mn |
| Sep 30, 2023 | 6.52 Mn |
| Jun 30, 2023 | -24.71 Mn |
| Mar 31, 2023 | -21.37 Mn |
| Dec 31, 2022 | -24.15 Mn |
| Sep 30, 2022 | -22.50 Mn |
| Jun 30, 2022 | -21.04 Mn |